Address of Medical Laboratory:
Customer Service Email:
Service Hotline:TEL：
Website：
YuceNeo has a sptial multi-omics experimental platform from genomics, transcriptomics, protein, molecule, pathology, and single cell aspects. The platform can provide one-stop testing services for the entire process of new drug development.
NGS
WES
YuceOne® Plus
TCR-seq
RNA-seq
IO360
GEP
Multimodal panel
Customized panel
Immunogenicity V-plex
Inflammatory factor V-plex
Multi-factor U-plex
PK/PD
Multicolor immunohistochemistry 9 colors
Immune microenvironment
Immune checkpoint treatment
Spatial gene expression profile
Single cell sequencing
●The Tumor Neoantigen Selection Alliance (TESLA) is composed of more than 30 neoantigen research institutions, including the famous Cancer Research Institute (CRI), the Parker Institute of Cancer Immunotherapy (PICI), the Memorial Sloan Kettering Cancer Center (MSKCC), and MD Anderson Cancer Center in the US. It aims to predict neoantigen through artificial intelligence algorithms, and ultimately produce more effective and targeted cancer vaccines tailored for each patient.
As the first Chinese member of the TESLA, YuceBio/YuceNeo has worked together with the alliance to establish a more accurate prediction system for neoantigen targets and promote the research and application of personalized tumor immunotherapy. The relevant research was published in Cell on October 9, 2020.
By simulating the biological process of generating neoantigen in the body, based on the real-world data accumulated by Yuce and its internationally leading machine learning models for optimization, an accurate screening algorithm for high-quality neoantigens, TruNeo™ of YuceNeo, is generated. The relevant literature has been published.
TruNeo™ accurately evaluates more than ten factors that affect neoantigen presentation, ensuring the accuracy of neoantigen screening. Analysis process of TruNeo™:
The literature has been published: Tang et al. BMC Bioinformatics (2020) DOI: 10.1186/s12859-020-03869-9
The "Ladder for Cancer Moonshot" is the first genomic cooperation project in China specifically designed for tumor immunotherapy. It was jointly launched by Shenzhen YuceBio Technology Co., Ltd. and Academician Zhan Qimin. The "Ladder for Cancer Moonshot" provides scientists and doctors in clinical tumor treatment with auxiliary treatment decision-making ability, provides for pharmaceutical companies with reliable target selection to develop drugs, and builds a cooperative, mutually beneficial, and win-win anti-cancer "ladder" to accelerate the clinical translation of the latest tumor immunotherapy.
Copyright©2021
Shenzhen yucebio Technology Co., Ltd. all rights reserved
Yueicp no.16128839
